Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Weight loss drugs Ozempic and Mounjaro might do more than slim waistlines — they could also help protect your brain. While major Alzheimer's trials came up short, researchers believe GLP-1 medications may still preserve memory and cognition in people with obesity or diabetes, especially when started early. Scientists are now calling for dedicated clinical trials to find out who benefits most.
Weight loss blockbusters like semaglutide (Ozempic) and tirzepatide (Mounjaro) may have an unexpected bonus: brain protection. Researchers from the University of Gothenburg and the University of Copenhagen reviewed the existing evidence and found that while GLP-1 medications show promise for cognitive health, the picture is more nuanced than headlines suggest.
On one hand, analyses of patient health records link GLP-1 treatment to a lower risk of dementia in people with type 2 diabetes. On the other hand, Novo Nordisk's EVOKE and EVOKE+ clinical trials found that semaglutide did not slow the progression of early Alzheimer's disease — even though it did affect several biological markers associated with the condition.
The researchers believe the real opportunity may lie elsewhere: in people with obesity or diabetes who experience metabolic-driven cognitive difficulties — like slower processing speed or trouble with attention and planning — rather than classic neurodegenerative disease.
Key Takeaways:
Why it matters: With obesity and diabetes affecting hundreds of millions globally, even a modest cognitive benefit from already-widely-used medications could have enormous public health implications — but only if we identify the right patients and the right timing.